Aardvark Therapeutics Inc (AARD)

Currency in USD
5.38
-0.35(-6.11%)
Closed·
5.380.00(0.00%)
·
AARD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
5.155.99
52 wk Range
3.3517.94
Key Statistics
Prev. Close
5.73
Open
5.72
Day's Range
5.15-5.99
52 wk Range
3.35-17.94
Volume
257.81K
Average Volume (3m)
247.92K
1-Year Change
-37.4419%
Book Value / Share
3.43
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AARD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
11.11
Upside
+106.53%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings upwards for the upcoming period

Aardvark Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

6 Buy
4 Hold
2 Sell
Ratings:
12 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 11.11
(+106.53% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
B.Riley
Buy7.00+30.11%8.00MaintainMay 15, 2026
BTIG
Hold---DowngradeMay 15, 2026
Morgan Stanley
Sell3.00-44.24%7.00DowngradeMay 15, 2026
Jones Trading
Buy19.00+253.16%33.00MaintainMar 24, 2026
Raymond James
Buy28.00+420.45%-MaintainMar 24, 2026

Earnings

Latest Release
Aug 11, 2026
EPS / Forecast
-0.66 / -0.87
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

AARD Income Statement

Compare AARD to Peers and Sector

Metrics to compare
AARD
Peers
Sector
Relationship
P/E Ratio
−1.7x−1.0x−0.4x
PEG Ratio
−0.28−0.020.00
Price/Book
1.6x2.5x2.6x
Price / LTM Sales
-8.1x3.1x
Upside (Analyst Target)
11.5%61.3%48.9%
Fair Value Upside
Unlock0.1%6.8%Unlock

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
1.13M5.17%6.08M
Other Institutional Investors
17.70M80.89%95.24M
Public Companies & Retail Investors
3.05M13.95%16.42M
Total
21.88M100.00%117.74M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Decheng Capital LLC17.90%3,917,29921,075
Decheng Capital Global Life Sciences Fund IV, L.P.13.52%2,958,88715,919

People Also Watch

6.09
JLHL
-1.46%
2.37
PN
0.00%
9.80
TTRX
-2.68%
3.10
DAIC
-7.19%
1.810
NCRA
-7.18%

FAQ

What Is the Aardvark Therapeutics (AARD) Stock Price Today?

The Aardvark Therapeutics stock price today is 5.38 USD.

What Stock Exchange Does Aardvark Therapeutics Trade On?

Aardvark Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Aardvark Therapeutics?

The stock symbol for Aardvark Therapeutics is "AARD."

What Is the Aardvark Therapeutics Market Cap?

As of today, Aardvark Therapeutics market cap is 117.74M USD.

What Is Aardvark Therapeutics's Earnings Per Share (TTM)?

The Aardvark Therapeutics EPS (TTM) is -3.20.

When Is the Next Aardvark Therapeutics Earnings Date?

Aardvark Therapeutics will release its next earnings report on Nov 12, 2026.

From a Technical Analysis Perspective, Is AARD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Aardvark Therapeutics Stock Split?

Aardvark Therapeutics has split 0 times.

How Many Employees Does Aardvark Therapeutics Have?

Aardvark Therapeutics has 28 employees.

What is the current trading status of Aardvark Therapeutics (AARD)?

As of Sep 06, 2026, Aardvark Therapeutics (AARD) is trading at a price of 5.38 USD, with a previous close of 5.73 USD. The stock has fluctuated within a day range of 5.15 USD to 5.99 USD, while its 52-week range spans from 3.35 USD to 17.94 USD.

What Is Aardvark Therapeutics (AARD) Price Target According to Analysts?

The average 12-month price target for Aardvark Therapeutics is 11.11 USD, with a high estimate of 28 USD and a low estimate of 3 USD. 6 analysts recommend buying the stock, while 2 suggest selling, leading to an overall rating of Buy. The stock has an +106.53% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.